Leadless Pacemaker Implant Location as a Predictor of Pacing Induced Cardiomyopathy

Authors:

Abstract
Background: Leadless pacemakers (LPs) avoid the lead‐ and pocket‐related complications of transvenous systems, but they pace exclusively from the right ventricle (RV), and chronic RV pacing carries a recognized risk of pacing‐induced cardiomyopathy (PICM). Whether implant location within the RV, a potentially modifiable factor, contributes to this risk has not been established. Methods: Patients undergoing LP implantation with ≥50% RV pacing, pre‐and post‐procedural echocardiograms, and post‐implant 3‐dimensional radiographic imaging were included. All implants targeted the RV septum per manufacturer recommendation. PICM was defined as ≥10% decline in left ventricular ejection fraction (LVEF) to P P <0.001) and discriminated free wall from non‐free wall implantation with an area under the receiver operating characteristic curve (AUC) of 0.85; a QRS duration of 172 ms provided optimal discrimination. Baseline LVEF, baseline QRS duration, and comorbidity burden did not differ between groups. Conclusions: Inadvertent free wall LP implantation is strongly associated with the subsequent development of PICM. Paced QRS duration is a readily available surrogate for implant location, and targeting a paced QRS duration below approximately 172 ms at the time of implant may serve as a practical, non‐invasive check on appropriate septal placement.
Funding Information
  • Biotronik
  • Boston Scientific Corporation
  • Medtronic

This publication has 8 references indexed in Scilit: